In this issue:
- Khorana for predicting VTE in chemotherapy recipients
- Predicting major bleeding during anticoagulation for unprovoked/weakly provoked VTE
- Four-factor PCC for FXa inhibitor-associated intracranial haemorrhage reversal
- Long-term splenectomy outcomes in paediatric autoimmune cytopenias
- DOACs for cerebral vein thrombosis
- Interferon-α vs. hydroxycarbamide in polycythaemia vera/essential thrombocythaemia
- Primary thromboprophylaxis with enoxaparin in symptomatic outpatients with COVID-19
- D-dimer and reduced dose apixaban after unprovoked VTE
- Impact of tamoxifen or aromatase inhibitors on thrombin generation
- Low-dose apixaban as secondary VTE prophylaxis in cancer
Please login below to download this issue (PDF)